Combinatorial Enzyme Therapy Against ESKAPE Pathogenic Biofilms offers the latest insights into ESKAPE pathogen biofilms, including their formation, structure, and resistance mechanisms and highlights innovative therapeutic strategies to combat them, with a specific focus on combinatorial enzyme therapies. The book begins with an overview of the significant burden these pathogens impose across healthcare and the food industry, laying the groundwork for understanding the intricate relationship between antibiotic resistance and biofilm dynamics. It advocates novel approaches through combinatorial enzymatic therapy, detailing the mechanisms and synergies of various enzymes in effectively dismantling biofilms. With insights into cutting-edge delivery systems, including nanotechnology and the integration of CRISPR-Cas systems and artificial intelligence, the book charts a course for the future of advanced therapeutic strategies. It concludes by addressing regulatory considerations, positioning combinatorial enzyme therapy as a promising frontier in the fight against persistent infections caused by ESKAPE pathogens
Table of Contents
1. Introduction to Biofilm and Antibiotic Resistance in ESKAPE Pathogen-Associated Diseases: Clinical Burden and Challenges2. Burden of ESKAPE Pathogens in the Food Industry
3. Co-relationship between Antibiotic Resistance and ESKAPE Pathogen Biofilm Formation
4. The Necessity of Combinatorial Enzymatic Therapy for ESKAPE Pathogen Biofilm Control
5. Mechanisms of Combinatorial Enzyme Therapy against the ESKAPE Pathogen Biofilm
6. Combinatorial Enzyme against ESKAPE Pathogen Biofilms: Carbohydrase, Protease, and Lipase Synergies
7. Combinatorial Nuclease Enzymes against ESKAPE Pathogen Biofilms with Clinical Application
8. Therapeutic Enzymatic Repurposing against the ESKAPE Pathogen Biofilm with Clinical Application
9. Nano Delivery of the Combinatorial Enzymes against the ESKAPE Pathogen Biofilm
10. CRISPR-Cas Systems and Artificial Intelligence Drive Combinatorial Enzyme Therapy against the ESKAPE Pathogen Biofilm
11. Future of Advanced Combinatorial Enzyme Therapy with Regulatory Aspects against the ESKAPE Pathogen Biofilm
Authors
Awanish Kumar Associate Professor and Head, Department of Biotechnology, National Institute of Technology Raipur, India. Dr. Awanish Kumar is an Associate Professor of the Department of Biotechnology at the National Institute of Technology, Raipur, Chhattisgarh, India. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery. Aditya Upadhyay PhD Scholar, Department of Biotechnology, National Institute of Technology, Raipur, CG, India.Aditya Upadhyay is a PhD Scholar at the Department of Biotechnology, National Institute of Technology in Raipur, India. His research focuses on infection biology, antibiotic resistance, and drug discovery in relation to biofilm formation. He holds a Master of Technology degree in Biotechnology (Honors) from Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, India and a Bachelor of Technology in Biotechnology from Dr. A.P.J Abdul Kalam Technical University, Lucknow, India. Aditya is currently working on the design of new drugs and therapies to treat salmonella biofilm infections and combat antibiotic resistance. He has published articles in various SCI journals and contributed book chapters.
